As of June 21, 2025, ALX Oncology Holdings Inc (ALXO) reports a Gross Margin of 9.32%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of ALX Oncology Holdings Inc's Gross Margin
Over recent years, ALX Oncology Holdings Inc's Gross Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2024-12-31 | 9.32% |
| 2023-12-31 | 8.47% |
| 2022-12-31 | 9.17% |
| 2021-12-31 | 9.18% |
This slight downward trend highlights how ALX Oncology Holdings Inc manages its operational efficiency and pricing power over time.
Comparing ALX Oncology Holdings Inc's Gross Margin to Peers
To better understand ALX Oncology Holdings Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| ALX Oncology Holdings Inc (ALXO) | 9.32% |
| Prelude Therapeutics Inc (PRLD) | 7775.20% |
| Kymera Therapeutics Inc (KYMR) | 7775.20% |
| Revolution Medicines Inc (RVMD) | 7775.20% |
| Cullinan Oncology Inc (CGEM) | 7775.20% |
| Arcus Biosciences Inc (RCUS) | 7775.20% |
Compared to its competitors, ALX Oncology Holdings Inc's Gross Margin is lower than all peers, suggesting potential challenges in production costs or pricing strategy.